Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory Factors
A pterygium is generally believed to be a chronic inflammatory lesion caused by external stimuli that develops from the conjunctiva and grows onto the cornea. Simple bare sclera excision is the most commonly used method to treat pterygium. However, the high postoperative recurrence rate of pterygium...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2019/9472782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565604745216000 |
|---|---|
| author | Qie Guo Xiao Li Meng-Na Cui Yu Liang Xiang-Peng Li Jun Zhao Li-Na Wei Xiao-Lei Zhang Xiang Hua Quan |
| author_facet | Qie Guo Xiao Li Meng-Na Cui Yu Liang Xiang-Peng Li Jun Zhao Li-Na Wei Xiao-Lei Zhang Xiang Hua Quan |
| author_sort | Qie Guo |
| collection | DOAJ |
| description | A pterygium is generally believed to be a chronic inflammatory lesion caused by external stimuli that develops from the conjunctiva and grows onto the cornea. Simple bare sclera excision is the most commonly used method to treat pterygium. However, the high postoperative recurrence rate of pterygium remains a persistent challenge. Mitomycin C (MMC) is an antineoplastic antibiotic that inhibits DNA, RNA, and protein synthesis. In recent years, although MMC has proven useful for the treatment of pterygium, its application has been controversial because of its clear toxicity and the possibility of ocular complications. In the current study, we prospectively recruited patients to receive or not receive a local injection of MMC (0.4 mg/ml). Follow-up was conducted with the patients to determine the postoperative recurrence rate of pterygium and/or to observe any ocular complications. The remarkable results demonstrated that MMC can decrease the postoperative recurrence rate of pterygium without leading to serious eye complications. Further results indicated that MMC can inhibit the activation of the NLRP3 inflammatory signalling pathway and thus downregulate the expression of downstream molecules, including IL-18 and IL-1β. MMC also reduced the expression of inflammatory factors TGF-β1, VEGF, and IL-6. In addition to influencing these factors, MMC suppressed neovascularization and the proliferation of corneal fibroblasts to effectively reduce the recurrence rate of pterygium. Taken together, our results provide a theoretical basis for the development of prevention and treatment strategies for pterygium and suggest that MMC is highly effective as an adjunctive treatment after excision of primary pterygia. |
| format | Article |
| id | doaj-art-be7c56db07e6425bae6b498b357f88f8 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-be7c56db07e6425bae6b498b357f88f82025-02-03T01:07:20ZengWileyJournal of Ophthalmology2090-004X2090-00582019-01-01201910.1155/2019/94727829472782Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory FactorsQie Guo0Xiao Li1Meng-Na Cui2Yu Liang3Xiang-Peng Li4Jun Zhao5Li-Na Wei6Xiao-Lei Zhang7Xiang Hua Quan8Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaDepartment of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, ChinaA pterygium is generally believed to be a chronic inflammatory lesion caused by external stimuli that develops from the conjunctiva and grows onto the cornea. Simple bare sclera excision is the most commonly used method to treat pterygium. However, the high postoperative recurrence rate of pterygium remains a persistent challenge. Mitomycin C (MMC) is an antineoplastic antibiotic that inhibits DNA, RNA, and protein synthesis. In recent years, although MMC has proven useful for the treatment of pterygium, its application has been controversial because of its clear toxicity and the possibility of ocular complications. In the current study, we prospectively recruited patients to receive or not receive a local injection of MMC (0.4 mg/ml). Follow-up was conducted with the patients to determine the postoperative recurrence rate of pterygium and/or to observe any ocular complications. The remarkable results demonstrated that MMC can decrease the postoperative recurrence rate of pterygium without leading to serious eye complications. Further results indicated that MMC can inhibit the activation of the NLRP3 inflammatory signalling pathway and thus downregulate the expression of downstream molecules, including IL-18 and IL-1β. MMC also reduced the expression of inflammatory factors TGF-β1, VEGF, and IL-6. In addition to influencing these factors, MMC suppressed neovascularization and the proliferation of corneal fibroblasts to effectively reduce the recurrence rate of pterygium. Taken together, our results provide a theoretical basis for the development of prevention and treatment strategies for pterygium and suggest that MMC is highly effective as an adjunctive treatment after excision of primary pterygia.http://dx.doi.org/10.1155/2019/9472782 |
| spellingShingle | Qie Guo Xiao Li Meng-Na Cui Yu Liang Xiang-Peng Li Jun Zhao Li-Na Wei Xiao-Lei Zhang Xiang Hua Quan Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory Factors Journal of Ophthalmology |
| title | Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory Factors |
| title_full | Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory Factors |
| title_fullStr | Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory Factors |
| title_full_unstemmed | Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory Factors |
| title_short | Low-Dose Mitomycin C Decreases the Postoperative Recurrence Rate of Pterygium by Perturbing NLRP3 Inflammatory Signalling Pathway and Suppressing the Expression of Inflammatory Factors |
| title_sort | low dose mitomycin c decreases the postoperative recurrence rate of pterygium by perturbing nlrp3 inflammatory signalling pathway and suppressing the expression of inflammatory factors |
| url | http://dx.doi.org/10.1155/2019/9472782 |
| work_keys_str_mv | AT qieguo lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT xiaoli lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT mengnacui lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT yuliang lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT xiangpengli lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT junzhao lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT linawei lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT xiaoleizhang lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors AT xianghuaquan lowdosemitomycincdecreasesthepostoperativerecurrencerateofpterygiumbyperturbingnlrp3inflammatorysignallingpathwayandsuppressingtheexpressionofinflammatoryfactors |